GSK (LON:GSK) Posts Quarterly Earnings Results

GSK (LON:GSK) issued its earnings results on Wednesday. The company reported GBX 23.20 ($0.29) EPS for the quarter, Digital Look Earnings reports. GSK had a net margin of 12.83% and a return on equity of 33.30%.

GSK Stock Down 2.6 %

GSK stock traded down GBX 38 ($0.47) on Friday, reaching GBX 1,441.50 ($17.93). 60,827,895 shares of the company traded hands, compared to its average volume of 31,635,686. The firm has a fifty day simple moving average of GBX 1,356.75 and a 200-day simple moving average of GBX 1,457.45. The company has a market cap of £58.81 billion, a P/E ratio of 1,275.66, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK has a one year low of GBX 1,282.50 ($15.95) and a one year high of GBX 1,823.50 ($22.68). The company has a debt-to-equity ratio of 123.04, a current ratio of 0.82 and a quick ratio of 0.73.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a research note on Tuesday, January 7th. Berenberg Bank decreased their target price on GSK from GBX 1,820 ($22.63) to GBX 1,600 ($19.90) and set a “buy” rating for the company in a research report on Friday, November 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.46).

Insider Transactions at GSK

In other GSK news, insider Jonathan Symonds bought 1,500 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was acquired at an average price of GBX 1,315 ($16.35) per share, with a total value of £19,725 ($24,530.53). Insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.